SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid signaling pathways to develop treatments for people with cancer, pain and neurological disorders, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences d’Artelo, was selected for an oral presentation at the 32n/a International Cannabinoid Research Society (ICRS) Symposium, Sunday June 26e. Dr. Sullivan will present preclinical data related to ART26.12, the company’s lead fatty acid binding protein 5 (FABP5) inhibitor. The Company plans to provide a summary of the research following the presentation. The ICRS Symposium is being held at Bailey Allen Hall, National University of Ireland, Galway, 25-30 June 2022.
“We are excited to participate in this important annual cannabinoid research conference and are excited to share our latest preclinical findings in the development of ART26.12,” said Gregory D. Gorgas, President and CEO of ‘Artelo Biosciences. “ART26.12 represents an important program in Artelo’s efforts to advance cancer control programs and supportive cancer care. »
Additionally, the Society will present the prestigious William A. Devane Young Investigator of the Year Award at the CIHR Symposium to an Outstanding Investigator on Wednesday, June 29.e. Past recipients of the Young Investigator program include Professor Saoirse O’Sullivan and Dr. Martin Kaczocha, Assistant Professor in the Department of Anesthesiology, Department of Biochemistry and Cell Biology, and Institute of Chemical Biology and Discovery of Medicines from Stony Brook University and Scientific Advisor to Artelo Biosciences.
About the International Cannabinoid Research Society
The International Cannabinoid Research Society (ICRS) is the world’s premier scientific association with over 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source of unbiased information on cannabis and cannabinoids, ICRS’ primary role is to provide an open forum for researchers to meet and discuss their research. Interested parties can follow @ICRS_Society on Twitter and use #ICRS2022 for the latest meeting updates.
CIHR William A. Devane Young Investigator of the Year
In 2018, Artelo announced a five-year commitment to sponsor the William A. Devane Young Investigator of the Year Award at the ICRS Annual Symposium. This award is a unique opportunity to identify and showcase researchers who have demonstrated dedication, perseverance, and skill in researching the endocannabinoid system. Past recipients, Dr. Saoirse O’Sullivan, 2016 winner, and Dr. Martin Kaczocha, 2017 winner, are currently helping Artelo advance its product portfolio.
Fatty acid binding proteins (FABPs) are a family of intracellular proteins that chaperone lipids, including endocannabinoids and fatty acids. Various FABP inhibitors may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective FABP5 inhibitor. During the development of our lead molecule for chemotherapy-induced peripheral neuropathy, additional compounds from our extensive library of potent and selective FABP inhibitors were identified and selected for progress to regulatory enabling studies in cancer and other areas of high unmet need where FABP inhibition holds great promise.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo offers a portfolio of broadly applicable product candidates designed to address significant unmet needs across multiple diseases and conditions, including anorexia, cancer, anxiety, pain and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies cutting-edge scientific, regulatory and business discipline to develop high-impact therapies. More information is available on www.artelobio.com and Twitter: @ArteloBio.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to product development of the Company, clinical and regulatory timelines, market opportunities, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements of a predictive nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate, as well as management’s current beliefs and assumptions. These statements can be identified by the use of forward-looking expressions, including, but not limited to, “expect”, “anticipate”, “intend”, “plan”, “believe”. , “estimate”, “potential”, “predict”, “project”, “should”, “would” and similar expressions and the negatives of these terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from the results, performance or achievements future expressed or implied by the forward-looking statements. research statements. These factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Contact with Investor Relations:
Crescendo Communications, LLC
Email: [email protected]